ScoreWhy is Alnylam Pharmaceuticals, Inc. ?
1
With a growth in Net Sales of 30.21%, the company declared Outstanding results in Jun 25
- NET PROFIT(HY) Higher at USD -49.61 MM
- INVENTORY TURNOVER RATIO(HY) Highest at 5.17 times
- CASH AND EQV(HY) Highest at USD 5,489.81 MM
2
Market Beating Performance
- The stock has generated a return of 64.58% in the last 1 year, much higher than market (S&P 500) returns of 15.98%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Alnylam Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Alnylam Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Alnylam Pharmaceuticals, Inc.
64.72%
3.67
43.55%
S&P 500
14.77%
0.81
19.85%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
48.13%
EBIT Growth (5y)
12.54%
EBIT to Interest (avg)
-3.79
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.21
Sales to Capital Employed (avg)
0.81
Tax Ratio
24.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
339.80
EV to EBIT
-338.77
EV to EBITDA
-676.03
EV to Capital Employed
-1589.07
EV to Sales
16.65
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-42.12%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
NET PROFIT(HY)
Higher at USD -49.61 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 5.17 times
CASH AND EQV(HY)
Highest at USD 5,489.81 MM
NET SALES(Q)
Highest at USD 773.69 MM
PRE-TAX PROFIT(Q)
At USD -20.1 MM has Grown at 40.14%
-11What is not working for the Company
NET PROFIT(Q)
At USD -51.02 MM has Fallen at -319.68%
ROCE(HY)
Lowest at -257.82%
RAW MATERIAL COST(Y)
Grown by 9.11% (YoY
DEBTORS TURNOVER RATIO(HY)
Lowest at 5.62 times
Here's what is working for Alnylam Pharmaceuticals, Inc.
Inventory Turnover Ratio
Highest at 5.17 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Net Sales
Highest at USD 773.69 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Sales
At USD 773.69 MM has Grown at 31.8%
over average net sales of the previous four periods of USD 587.02 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Pre-Tax Profit
At USD -20.1 MM has Grown at 40.14%
over average net sales of the previous four periods of USD -33.58 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Cash and Eqv
Highest at USD 5,489.81 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Alnylam Pharmaceuticals, Inc.
Net Profit
At USD -51.02 MM has Fallen at -319.68%
over average net sales of the previous four periods of USD -12.16 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Debtors Turnover Ratio
Lowest at 5.62 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Raw Material Cost
Grown by 9.11% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
